Knight Therapeutics (TSX:GUD) Common Stock : C$534.3 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Common Stock?

Knight Therapeutics's quarterly common stock declined from Jun. 2024 (C$540.9 Mil) to Sep. 2024 (C$539.3 Mil) and declined from Sep. 2024 (C$539.3 Mil) to Dec. 2024 (C$534.3 Mil).

Knight Therapeutics's annual common stock declined from Dec. 2022 (C$599.1 Mil) to Dec. 2023 (C$540.0 Mil) and declined from Dec. 2023 (C$540.0 Mil) to Dec. 2024 (C$534.3 Mil).

Knight Therapeutics Common Stock Historical Data

The historical data trend for Knight Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Common Stock Chart

Knight Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

694.35

628.85

599.06

540.05

534.27

Knight Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															540.05	540.13	540.95	539.32	534.27

Knight Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Janice Jean Murray	Director
Nicolas Sujoy	Director
Long Zone Holdings Inc.	10% Security Holder
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines